Physician profile
Ashley Weng
NPI 1386164101
$2,269.38
in general payments reported to CMS, 2019-2025
10 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $54.92 · 2022: $361 · 2023: $175 · 2024: $1,395 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Food and Beverage | $653.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $1,432.92 | 2022-2024 | Vyvgart |
| Astrazeneca Pharmaceuticals LP | $320.97 | 2024-2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $122.09 | 2022 | |
| Kyowa Kirin, INC. | $121.16 | 2022 | |
| Csl Behring | $116.69 | 2020-2023 | Hizentra |
| Grifols USA, LLC | $78.42 | 2023 | Gamunex-C |
| Novo Nordisk INC | $23.86 | 2025 | Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $18.80 | 2024 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $18.58 | 2020 | |
| Sk Life Science, INC. | $15.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.